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Background: Neurofibromatosis type 2 (NF2) is an autosomal dominant syndrome 
with a frequency of 1 in 25,000 live births and a penetrance of almost 100% by 
the sixth decade of life. The main tumors occurring in NF2 patients are bilateral 
vestibular schwannomas, other peripheral, cranial and spinal nerve schwannomas, 
intracranial and intraspinal meningiomas, ependymomas, and gliomas.
Case Description: We report the case of a 6‑year‑old boy who presented with 
a 1‑month history of nausea and recurrent vomiting. Physical examination was 
positive for ataxic gait and left‑sided facial nerve palsy. Family history was positive 
for NF2 in the patient’s father and paternal uncle. Magnetic resonance imaging 
brain revealed a solid enhancing lesion arising from the right cerebellar cortex, 
which was effacing the fourth ventricles and causing hydrocephalus. Craniotomy 
and excision of the lesion were performed. Histopathology report confirmed the 
diagnosis to be desmoplastic medulloblastoma. Based on the patients’ subsequent 
history and family history, he was diagnosed to be a case of NF2.
Conclusion: This is the first case of medulloblastoma occurring in a patient with 
NF2 and raises the possibility of an association between medulloblastoma and NF2.
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BACKGROUND
Neurofibromatosis type 2 (NF2) is an autosomal 
dominant syndrome with a frequency of 1 in 25,000 live 
births and a penetrance of almost 100% by the sixth 
decade of life.[2] It has a variable presentation, resulting 
from the mutation in the tumor suppressor gene 
merlin, which is located on chromosome 22q, and 
is a predominantly intracranial condition with its 
characteristic bilateral vestibular schwannomas.[15] The 
other main tumors occurring in NF2 patients are other 
peripheral, cranial and spinal nerve schwannomas, 
intracranial and intraspinal meningiomas, ependymomas 
and gliomas.[6] Four large clinical studies have been 
conducted which confirm the aforementioned clinical 
picture.[4,10,11,12] These tumors are mostly benign and 
grow slowly, but their location within the central nervous 
system can cause great morbidity and mortality.[9]
Clinical presentation of most patients with NF2 includes 
hearing loss which is usually unilateral, with or without 
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tinnitus.[6] NF2 is diagnosed clinically after a patient 
fulfills a predefined criteria.[5]
Herein, we report a case NF2 presenting with recurrent 
vomiting and headache that was diagnosed with 
medulloblastoma. This, to the best of our knowledge, 
is the first case of medulloblastoma occurring in an 
NF2 patient.
CASE REPORT
A 6‑year‑old boy of average height and weight presented 
to the ER in 2003 with complaints of repeated vomiting 
and headache for 1‑month. He was a student of a 
local public school, his past medical history being 
unremarkable; his immunization status was complete, 
and there were no known allergies. In family history, the 
patient’s father and uncle (father’s brother) were known 
to have NF2. On physical examination, he was vitally 
stable. Positive findings included left‑sided facial nerve 
palsy and ataxic gait.
After a series of initial investigations, magnetic resonance 
imaging (MRI) brain was done. The report described 
a solid mass arising from the right cerebellar cortex, 
which was isointense to the gray matter on T1‑weighted 
images and hypo to isointense to the gray matter on 
T2‑weighted images. Postcontrast images showed an 
intense enhancement, which was almost homogenous. 
The mass was causing effacement of the fourth ventricles 
with dilatation of the third and lateral ventricles. The 
vertical height of the lesion was 4.2 cm; AP dimension 
was 4 cm, and the transverse diameter was 4.8 cm. There 
was no evidence of intracranial hemorrhage. Gray and 
white matter signals of supratentorial brain were within 
normal limits. No midline structural defect was seen. The 
differential diagnoses of medulloblastoma or astrocytoma 
were made.
The patient underwent craniotomy and excision of 
the lesion with the insertion of a ventriculoperitoneal 
shunt. The histopathology report described a malignant 
infiltrating tumor present in sheets [Figure 1]. The tumor 
was composed of small oval to indented basophilic cells, 
exhibiting nuclear hyperchromasia [Figures 1 and 2]. 
Extensive necrosis [Figure 3] and karyorrhexis were identified 
with areas of hemorrhage. Brisk mitotic figures were also 
seen [Figure 4]. The tumor cells showed positivity for 
immunohistochemical stain CD 56 [Figure 5]. Focal 
positivity for immunohistochemical stain glial fibrillary 
acidic protein was also seen [Figure 6]. Based on these 
findings a final diagnosis of desmoplastic medulloblastoma 
was made.
The patient underwent metastatic workup which was 
negative. After discharge, he was kept under close 
follow‑up. Pediatric oncology team was taken on board 
and after discussing the case at the tumor board meeting, 
a multidisciplinary approach was taken and both 
chemotherapy and radiotherapy were administered.
Figure 1: Patternless sheets of primitive appearing neoplastic cells 
with hyperchromatic nuclei with neuropil
Figure 2: Primitive appearing neoplastic cells with hyperchromatic 
nuclei, scant cytoplasm, and indistinct cell borders
Figure 3: Tumor with areas of necrosis as indicated by the arrow 
(H and E, ×20)
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In 2003, he was found to have a 1.0 cm × 1.5 cm skin 
colored nodule on this left forearm, which was excised 
with histopathology of the lesion revealing benign 
peripheral nerve sheath tumor.
In 2004, during a routine MRI scan the patient was 
found to have a cerebellar lesion for which he underwent 
craniotomy and excision of the lesion. Biopsy of the 
excised specimen revealed postchemotherapy and 
radiotherapy gliosis. He was then again kept under close 
follow‑up. He complained of vision disturbances in 
2006 and after an ophthalmological exam, was diagnosed 
to have right eye cataract for which he underwent 
phacoemulsification and insertion of the intraocular lens.
Till 2010, his routine follow‑up MRI scans showed no 
significant pathological changes. However, in 2010, he 
again started complaining of vision disturbances and 
ophthalmological examination revealed right‑sided 
posterior capsular opacification and left‑sided cataract. 
He underwent left capsulectomy.
Over the span of next 3 years the patient remained 
well however, in 2013, he was again brought to Aga 
Khan University Hospital with complaints of headache, 
vomiting, and gait disturbances. MRI brain showed right 
superior frontal, inferior frontal, parasagittal and left 
posterior parietal meningiomas; excision of the lesions 
was performed.
Considering his case history and his family history, a 
diagnosis of NF2 was considered for him. A neurologist 
was taken on board; the NIH criterion was applied, and 
the patient was diagnosed to have NF2.
After the surgery in 2013, the patient has not been 
reported any symptoms. The follow‑up MRI scans have 
not revealed any positive findings.
DISCUSSION
NF is a genetic disorder of the nervous system. It became 
widely recognized in the 19th century,[1] but it has a wide 
pictorial history that traces back to the 13th century.[3] 
The neuromas of NF were first described, in 1849.[3] Von 
Recklinghausen’s is credited with the discovery of NF 
and coined the name of this disorder, in 1882.[3] Research 
on NF increased between 1909 and 1990 after Joseph 
Merick, the famous Elephant Man, was erroneously 
diagnosed with NF1.[3]
NF is considered to have two distinct types, NF1 and 
NF2.[14] NF1 has more peripheral manifestations and 
NF2 carries predominantly central manifestations. Over 
the past two decades, our knowledge of the genetics 
and management of NF has dramatically increased. The 
two forms of NF have been shown to be two distinct 
entities, both at clinical and molecular levels.[14] NF 
also has other rarer forms with outlying phenotypes and 
atypical presentations. These unconventional and atypical 
forms have been delineated and include hereditary spinal 
Figure 4: Neoplastic cells showing prominent mitotic figures as 
pointed out by the arrow (H and E, ×40)
Figure 5: Tumor cells showing positivity for immunohistochemical 
stain CD56
Figure 6: Tumor cells showing focal positivity for immunohistochemical 
stain glial fibrillary acidic protein
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NF, schwannomatosis, familial intestinal NF, autosomal 
dominant “café au lait” spots alone, Watson syndrome, 
autosomal dominant “neurofibromas” alone, Noonan 
syndrome and the syndrome of multiple naevi, multiple 
schannomas, and multiple vaginal leiomyomas.[14]
NF2 is often a devastating autosomal dominant disorder 
which until recently was confused with its more common 
namesake NF1.[6] NF2 is a multiple neoplasia syndrome 
that results from a mutation in NF2 tumor suppressor 
gene on chromosome 22.[2] Affected patients carry a 
dominant loss of function mutation of the merlin gene 
on chromosome 22. Merlin is a cytoskeletal protein 
that functions as a tumor suppressor by facilitating 
E‑cadherin‑mediated contact inhibition.
NF2 inevitably develops schwannomas, typically affecting 
both the vestibular nerves, resulting in hearing loss and 
deafness. Most of the patients present with hearing loss 
which is unilateral at onset and may be accompanied 
or preceded by tinnitus.[7] Vestibular schannomas may 
also cause dizziness or imbalance as first symptoms. 
Nausea, vomiting or true vertigo are rare symptoms, 
occurring more commonly in the later stages.[7] The 
other tumors seen in NF2 are schwannomas of other 
cranial, spinal, and peripheral nerves. Furthermore, 
NF2 is associated with intracranial and intraspinal 
meningiomas and low‑grade central nervous system 
malignancies like ependymomas.[7] As mentioned 
previously, both meningiomas and schwannomas were 
seen in our patient. Ophthalmic manifestations are also 
present in NF2 and include reduced juvenile cataracts, 
as seen in our patient, and retinal hamartomas.[8] About 
70% of NF2 cases have skin tumors with intracutaneous 
plaque like lesions or more deep‑seated tumors.[7]
Medulloblastoma is an aggressive posterior fossa brain 
tumor. Although medulloblastoma has been reported in 
patients with NF1, one study found the prevalence of 
posterior fossa tumors in NF1 to be 0.83%, there is no 
reported case of medulloblastoma occurring in a patient 
with NF2.[13]
To the best of our knowledge, this is the first case of 
medulloblastoma in a patient with NF2. The literature 
review conducted for this report could not find any case 
report or research study relating medulloblastoma and 
NF2. This raises the possibility of an association between 
these two disease entities and shows that even NF2 can 
also have this posterior fossa brain stem tumor.
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